meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 1st line (L1)
11
mRCC - L1 - PDL1 negative
1
mRCC - L1 - PDL1 positive
4
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
no study with result for this clinical condition